MUTE-Seq is a new liquid-biopsy method powered by an engineered ultra-precise CRISPR enzyme, FnCas9-AF2, which can distinguish single-base mismatches across all sgRNA positions with near-zero ...

Revvity targets 2026 growth with multiomics, AI-powered base editing, NGS newborn screening, and immunotherapy advances.

Liquid biopsy is increasingly recognized as a promising tool for cancer detection and treatment monitoring, yet its effectiveness is often limited by ...

Cornell (NY, USA) researchers have found that a new DNA sequencing technology can be used to study how transposons move ...

In the past twenty years, major technological advances in extracting and analyzing DNA have transformed the ability to ...

First and only company with 100 approved and active companion diagnostic indications for next-generation sequencing in the ...

Comparing proteomics to genomics reveals essential insights into their contributions to systems biology and experimental ...

NeoGenomics will present new data at ASH on how comprehensive genomic profiling supports diagnosis and treatment decisions in ...

JAK2 gene fusion appears across multiple CTCL types, shaping diagnosis and treatment opportunities. Learn more about its ...

A new study shows that thanks to cheaper DNA testing, we've reclassified more mammal species and have more biodiversity.

Sediment DNA also traces life outside the cave. Predators dragged prey into sheltered chambers, humans left waste behind. By ...

Gene Fusion Testing Market to reach USD 2.5 Bn by 2035 at 12.1% CAGR, driven by rising cancer incidence and demand for ...